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Steroid response in refractory Asthmatics
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Inhaled glucocorticosteroids are currently the most effective anti-inflammatory controller medications for treating 
persistent asthma. The efficacies of glucocorticoids include reducing asthma symptoms, reducing exacerbation 
frequency, improving quality of life, improving lung function, decreasing airway hyperresponsiveness, controlling airway 
inflammation, and reducing mortality. However, the treatment response to glucocorticosteroids in asthmatics varies, 
and certain subtypes of asthma, such as refractory asthma, respond poorly to high-dose inhaled glucocorticoid and 
systemic steroids. The medical costs of treating refractory asthmatics represent about 50% of the total healthcare cost 
for asthma. A thorough understanding of the mechanisms of glucocorticoid action, patient responses to glucocorticoids, 
and steroid resistance observed in refractory asthmatics is necessary for the targeted development of therapeutic 
drugs. This review discusses the characteristics of severe refractory asthmatics and the mechanisms of steroid 
response and resistance in asthma treatment.
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INTRODUCTION
Asthma is a chronic inflammatory airway disease 
involving episodic breathlessness and wheezing with 
airway hyperresponsiveness to environmental stimuli 
[1-3]. Airway inflammation in asthmatic patients is 
characterized by degranulated mast cells, infiltrat-
ing eosinophils, and an increased number of activated 
helper T-lymphocytes [1-3]. In asthma, many differ-
ent inflammatory mediators such as lipid mediators, 
inflammatory peptides, chemokines, cytokines, and 
growth factors are increased [1-3]. The structural cells 
of the airways, including epithelial cells, airway smooth 
muscle cells, endothelial cells, and fibroblasts, also are a 
major source of inflammatory mediators in asthma [3]. 
Airway remodeling in both large and small airways has 
been documented in all degrees of asthma severity [4]. 
Structural changes in airway remodeling include loss 
of epithelial integrity, thickening of the basement mem-
brane, subepithelial fibrosis, goblet cell and submucosal 
gland enlargement, increased smooth muscle mass, 
decreased cartilage integrity, and increased airway 
vascularity [4-7]. Inhaled glucocorticoids are currently 
the most effective anti-inflammatory controller medica-
tions for the treatment of persistent asthma [1-3] in Ko-
rea [1,2] and are recommended by the Global Initiative 
for Asthma (GINA) guidelines [3].
The prevalence of asthma is about 5-10% of the gener-
al population. Of these, approximately 5-10% are severe 
refractory asthmatics who respond poorly to asthmatic 
drugs, including high-dose inhaled steroids [5-12]. Se-
vere refractory asthmatics have persistent symptoms, 
frequent symptom exacerbation, and severe airway ob-
struction even when taking high-dose inhaled steroids. 144    The Korean Journal of Internal Medicine Vol. 27, No. 2, June 2012
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The subtypes of severe asthma [13-18] include fatal or 
near fatal asthma, steroid-dependent asthma, steroid-
resistant asthma, difficult-to-control asthma, poorly 
controlled asthma, brittle asthma, and irreversible 
asthma. Patients who do not reach an acceptable level 
of control at step 4 of the GINA guidelines (reliever 
medication plus two or more controllers) are defined as 
having difficult-to-control asthma [3]. The American 
Thoracic Society [16] has defined refractory asthma (RA) 
as followings. RA was defined by one or both major 
criteria and one minor criteria as followings: 1) major 
criteria: treatment with continuous or near continuous 
(> 50% of year) oral corticosteroids (CS), requirement 
for treatment with high-dose inhaled CS; 2) minor crite-
ria: a) requirement for daily treatment with a controller 
medication in addition to inhaled CS, e.g., long-acting 
β-agonist, theophylline, or leukotriene antagonist, b) 
asthma symptoms requiring short-acting β-agonist 
use on a daily or near daily basis, c) persistent airway 
obstruction (forced expiratory volume in one second 
[FEV1] < 80% predicted, diurnal peak expiratory flow 
[PEF] variability > 20%), d) one or more urgent care 
visits for asthma per year, e) three or more oral steroid 
“bursts” per year, f) prompt deterioration with ≤ 25% 
reduction in oral or inhaled corticosteroid dose, g) near 
fatal asthma event in the past. 
This review discusses the characteristics of severe 
asthma, including RA, and the mechanisms of steroid 
response and steroid resistance in the treatment of 
asthma.
CHARACTERISTIC OF SEVERE ASTHMA
Subtypes of difficult-to-control asthma (Table 1)
Brittle asthma is diagnosed in patients with severe 
and unstable asthma who maintain a wide variability 
of PEF despite high doses of inhaled steroids. Type 1 
brittle asthma is characterized by a wide, persistent, 
and chaotic PEF variability (> 40% diurnal variation 
for > 50% of the time over a period of at least 150 days) 
despite considerable medical therapy. Type 2 brittle 
asthma involves sudden acute attacks without an obvi-
ous trigger and lasting less than 3 hours in patients with 
apparently normal airway function or well-controlled 
asthma. 
Nocturnal asthma has an early morning dip and dou-
ble dip. Premenstrual asthma is unstable asthma that 
occurs 2-5 days before menses. Steroid-resistant asth-
ma is diagnosed in those rare patients who take high-
dose steroids (10- to 14-day course of prednisone ≥ 20 
mg twice daily), but experience less than 15% improve-
ment from baseline FEV1. Steroid-dependent asthma is 
defined as asthma that can be controlled only with high 
doses of oral steroids; it may be part of a continuum 
with steroid-resistant asthma at the other extreme. 
Acute and severe asthma are diagnosed in patients 
with acute or subacute exacerbation with dyspnea, 
wheezing, chest tightness, and decreased lung function. 
Status asthmaticus leads to acute respiratory failure 
and can cause death (fatal asthma). Severe asthma is 
classified according to cell type, e.g., eosinophils and 
neutrophils [18-21]. Eosinophilic asthma observed on 
bronchoalveolar lavage and mucosal biopsy causes de-
creased lung function and occasional near-fatal events.
Clinical characteristics of severe asthma
Severe asthma, including RA, represents 10-20% of 
asthma cases and is associated with more drug medica-
tions and more hospital visits and admissions than mild 
to moderate asthma. Mortality occurs in 3-35% of se-
vere asthma cases, and the medical cost to treat severe 
asthma is more than 50% of the total medical cost for 
treating asthmatic patients [22]. 
Risk factors for severe asthma are genetic and en-
vironmental, including many kinds of aeroallergens, 
beta-blockers, and anti-inflammatory drugs. Gastro-
esophageal reflux disease can affect asthma symptoms 
Table 1. Subtypes of difficult to control asthma 
Steroid-resistant asthma 
Steroid-dependent asthma 
Brittle asthma
Asthma with fixed obstruction
Adult-onset asthma
Nocturnal asthma
Aspirin-induced asthma
Premenstrual asthma
Acute, severe asthma
Status asthmaticus
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through esophagopharyngeal reflux and aspiration. In 
addition, factors such as denial, anxiety, fear, depres-
sion, socioeconomic status, and alcohol consumption 
can exacerbate asthma. Differential diagnoses [17] 
include smoking, chronic obstructive pulmonary dis-
ease, bronchiectasis, allergic bronchopulmonary as-
pergillosis, chronic infection, rhinosinusitis, vocal cord 
dysfunction, thyroid diseases, and inappropriate drug 
use. Among the genetic factors reported to be related 
to severe asthma are genetic variants of interleukin 
(IL)-4, IL-4 receptor, IL-9, IL-10, IL-1α, glutathione 
S-transferase, β2 receptor homozygous Gly-16 polymor-
phism, transforming growth factor (TGF)-β1, monocyte 
chemotactic protein, leukotriene C4 synthase, and 5-li-
poxygenase [23-26].
Pathophysiological characteristics of severe 
asthma
Severe asthma can be classified based on four differ-
ent pathological aspects. 
1) Persistent airway inflammation despite maximal 
medication occurs in one-half to two-thirds of patients 
with severe asthma. In these patients, an increase in 
T-lymphocyte activating mediator is seen on mucosal 
biopsy; increases in the innate response factor tryptase, 
TGF-β2, cysteinyl leukotrienes, and 15-hydroxyeicosa-
tetraenoic acid are found in the bronchoalveolar lavage 
fluid; and a thickening of the subepithelial basement 
membrane is observed [27]. 2) Severe asthma can be 
categorized based on the number of neutrophils or eo-
sinophils [28]. An increase in the number of neutrophils 
can result in bronchiolitis obliterans, and a decrease 
in the number of eosinophils can be caused by steroid 
treatment [19-21]. 3) Severe asthma is associated with 
high-grade airway remodeling characterized by base-
ment membrane thickening, epithelial denuding, airway 
smooth muscle thickening, and angiogenesis [4-6]. Sub-
mucosal fibroblasts secrete TGF-β, eotaxin, IL-4, and 
IL-13, causing collagen deposition and basement thick-
ening. Activated macrophages secrete immunoglobulin, 
collagen I, collagen III, tenascin, and fibronectin, lead-
ing to reticular basement thickening and subepithelial 
fibrosis [29]. Reticular basement thickening is related to 
asthma severity [30,31]. 4) Severe asthma can also be 
classified according to changes in both large and small 
airways [32]. 
MECHANISMS OF STEROID
Steroid responses
Glucocorticoids, the mainstay of asthma manage-
ment, bind to glucocorticoid receptors (GRs) in the 
cytosol, thereby activating the translocation of GRs to 
the nucleus. In the nucleus, GR binds to specific gene 
regulatory elements to induce the expression of genes 
involved in regulating airway inflammation (Table 2)
[33]. 
In a study of steroid responses in patients with mod-
erate to severe asthma, the relationship between re-
sponsiveness and the FEV1% predicted and blood and 
sputum eosinophil levels prior to glucocorticoid inhala-
Table 2. Effect of corticosteroids on gene transcription   
Increased transcription
Annexin-1 (lipocortin-1, phospholipase A2 inhibitor)
β2-adrenoceptors
Clara cell protein (CC10, phospholipase A2 inhibitor)
Glucocorticoid-induced leucine zipper protein
Interleukin (IL)-1 receptor antagonist
IL-1 receptor 2 (decoy receptor)
Inhibitor of NF-κB (IκB-α)
IL-10
Mitogen-activated protein kinase phosphatase-1
Secretory leukoprotease inhibitor
Decreased transcription
Cytokines
IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-16, IL-17,   
IL-18, TNFα, GM-CSF, stem cell factor
Chemokines
IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxins
Adhesion molecules
E-selectin, ICAM-1, VCAM-1 
Inflammatory enzymes
Cytoplasmic phospholipase A2
Inducible cyclooxygenase (COX-2)
Inducible nitric oxide synthase
Inflammatory receptors
Bradykinin B2-receptors
Tachykinin NK1-receptors, NK2-receptors
Peptides
Endothelin-1
Reprinted from Barnes [33] with permission from Elsevier.  
TNF, tumour necrosis factor; GM-CSF, granulocyte–macrophage 
colony stimulating factor; RANTES, released by normal activated 
T cells expressed and secreted; MIP, macrophage inflammatory 
protein; MCP, monocyte chemoattractant protein; ICAM, 
intercellular adhesion molecule; VCAM, vascular–endothelial cell 
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tion were investigated [28]. In this study, 86 adult asth-
matic outpatients with an initial FEV1 < 80% received 
a glucocorticoid inhalant (fluticasone propionate 1,000 
μg/day) for 4 weeks. The percentage change in FEV1 
after treatment was determined as [(FEV14 weeks - FE-
V1baseline) / FEV1baseline)] × 100. The asthmatic patients 
showing a change of > 12% in FEV1 (n = 46, 53.4%) 
after treatment had a significantly higher proportion of 
blood eosinophils and a lower FEV1 volume (in liters) 
prior to treatment. The percentage change in FEV1 cor-
related with the number of sputum eosinophils prior 
to glucocorticoid inhalation (r = 0.242; p < 0.05) and 
correlated inversely with the FEV1% predicted prior to 
glucocorticoid inhalation (r = -0.462; p < 0.001). Thus, 
the FEV1% predicted and blood and sputum eosinophil 
levels prior to glucocorticoid inhalation were associated 
with the responsiveness to inhaled glucocorticoids in 
patients with moderate to severe asthma.
There was a wide range of steroid responsiveness in 
asthmatics with moderate to severe asthma in the above 
study [28] (FEV1, -21 to 126.8%; forced vital capacity,   
-20 to 47%; forced expiratory flow, -55.1 to 95%) (Fig. 
1). This emphasizes the importance of investigating the 
mechanisms responsible for steroid unresponsiveness 
in asthma treatment. Korean and GINA guidelines [1-3] 
recommend a treatment strategy according to asthma 
control status, but the guidelines do not address the 
non-responder group. Potential new drugs are neces-
sary to reverse steroid unresponsiveness in controlling 
asthma symptoms in refractory asthmatics. 
The following factors must be considered when using 
high-dose inhaled steroids or systemic steroids to treat 
RA: 1) method of drug delivery, e.g., steroid inhaler; 2) 
presence of environmental factors that may aggravate 
asthma symptoms; 3) possibility of co-morbid diseases 
such as vocal cord dysfunction, gastroesophageal reflux 
disease, and chronic sinusitis; 4) psychological fac-
tors and patient compliance in taking asthmatic drugs; 
5) presence of infections (Chlamydia Mycoplasma); 6) 
possible failure in activation or rapid clearance of pred-
nisolone; and 7) simultaneous administration of other 
medications such as rifampin, phenytoin, carbarmaze-
pin, phenobarbital, and anticonvulsants. 
Steroid resistance
Those rare patients with steroid-resistant asthma ex-
hibit less than 15% improvement in baseline FEV1 after 
a 10- to 14-day course of high-dose steroids (prednisone 
≥ 20 mg twice daily). Proposed mechanisms leading to 
steroid resistance in asthma include intrinsic defects 
in neutrophils and mast cells, airway structural abnor-
malities, increases in inflammatory mediators related to 
steroid receptors, decreases in steroid receptor number 
and/or binding capacity, increases in GR-β, transcrip-
tional factor repression, existence of steroid-resistant 
neutrophils, imbalance between acetylation and deacet-
ylation, and airway remodeling [6,34,35]. 
Factors that may contribute to steroid resistance are 
listed in Table 3 [35,36]. These include a decreased 
number and/or genetic variation of GR; abnormal GR 
binding capacity; decreased DNA-binding activity of 
GR; alterations in transcription factors such as AP-1; 
immune dysregulation related to cytokines, chemo-
kines, IL-4, p50 nuclear factor-ĸB, or signal transducer 
and activator of transcription-4; mitogen-activated 
protein kinase phosphatase-2 single nucleotide poly-
morphism; increased neutrophils; viral infections; al-
lergens; mycobacterial infections; and smoking. 
NEW THERAPEUTIC DRUG TRIALS IN RA
Currently, clinical trials are evaluating several drugs 
for the treatment of severe asthma and RA, including 
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Figure 1. Change in forced expiratory volume in one second 
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methotrexate, gold, cyclosporine, intravenous gamma 
globulin, and macrolide antibiotics. However, the ef-
fects of these drugs on severe RA are minimal. In addi-
tion, phosphatidylinositol 3-kinase inhibitors, activated 
p38 mitogen-activated protein kinase inhibitors, and 
vitamin D3 to induce IL-10 production are undergo-
ing therapeutic trials. Recent medical advances in the 
pathophysiological mechanism of asthma have led to 
the development of many asthma drugs [36-40]. New 
steroids, new bronchodilators, phosphodiesterase-4 
inhibitors, transcription factor inhibitors, adhesion in-
hibitors, mediator antagonists, antioxidants, anti-IgE 
antibodies, cytokine inhibitors and antagonists, chemo-
kine receptor inhibitors and agonists, and sublingual 
immunotherapy have been developed [41]. 
CONCLUSIONS
Glucocorticoids are mainstay therapeutic drugs for 
decreasing airway inflammation in asthma. Refractory 
asthmatics represent 5-10% of all asthmatics, but ac-
count for more than 50% of the total treatment cost of 
asthma. Understanding the pathophysiology of severe 
asthma, RA, and steroid-resistant asthma is neces-
sary for the development of effective therapeutics. In 
order to develop individualized treatment approaches 
to severe RA, continued research is needed to identify 
genetic and environmental factors and to define the 
mechanisms of ongoing immune regulation and steroid 
responses. 
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